uphold mesh for the surgical treatment of uterine-predominant prolapse

Conditions: Pelvic Organ Prolapse

Summary: the primary objective of this study is to evaluate the efficacy of the upholdtm lite mesh over a 12 month follow up period, using a composite outcome including a good anatomical correction for both anterior and apical compartments (stage 0 or 1), no prolapse (bulge) symptoms (answer "no" at question 3 of the pfdi-20) and no reintervention for recurrent prolapse of the anterior or apical compartment.

secondary objectives include the evaluation of the following: * change from baseline of pop-q scoring at 6 weeks, 6 months and 12 months post procedure, including evolution of treated or non-treated posterior compartments. * the proportion of patients with anatomical prolapse (c/d), but who are asymptomatic. * change from baseline of mean quality-of-life scores. * evaluation of mesh properties from procedure date through study period. * peri-operative and post-treatment pain score assessment comparing the various anesthesia regimes used (visual analog scale). * assessment of patient subjective outcomes for overall treatment effects and satisfaction. * objective evaluation of mesh shrinkage by standardized ultrasound measurements.

Eligibility criteria:
inclusion criteria: * the patient must have given his/her informed and signed consent * the patient must be insured or beneficiary of a health insurance plan * the patient is available for 12 months of follow-up * patients with symptoms and altered quality of life in relation to uterine or post-hysterectomy vault prolapse * patients who are receiving the upholdtm lite mesh kit * female patients \>= years who have no desire of future pregnancy * diagnosed with pelvic organ prolapse and \>= ics pop-q stage 2 symptomatic prolapse apical compartment (uterine or vault), associated with ics pop-q stage 2 or 3 symptomatic prolapse anterior compartment (point ba \>= -1 * patients willing to complete quality of life questionnaire at baseline (pre-procedure) and at 6 weeks, 6 and 12 months post-procedure exclusion criteria: * the patient is participating in another study * the patient is in an exclusion period determined by a previous study * the patient is under judicial protection, under tutorship or curatorship * the patient refuses to sign the consent * it is impossible to correctly inform the patient * the patient is pregnant, parturient, or breastfeeding * patients who are not receiving the upholdtm lite mesh kit * patients \< 50 years * patients qho, according to the clinical judgment of the investigator, are not suitable for this study * patients who are considering future pregnancies * patients whose pelvic organ prolapse is a \<= 1 ics stage * patients requiring posterior graft procedure * patients with known or suspected hypersensitivity to polypropylene * patients with any pathology which ould compromise implant placement * patients with any pathology which ould compromise implant placement as mentioned in the device instruction manual * patients with any pathology that would limit blood supply and compromise healing * patients with blood coagulation disorder (associated current level coagulation) * patients with autoimmune connective tissue disease * patients with upper urinary tract obstruction and renal insufficiency * patients with local or systemic infection